• 1. DsbA is a redox-switchable mechanical chaperone
  Edward C. Eckels,Deep Chaudhuri,Soham Chakraborty,Daniel J. Echelman,Shubhasis Haldar Chem. Sci. 2021 12 11109
• 2. Synthesis of aromatic 1,2-disulfonimides and their prospects as monomers
  Denis Andzheevich Sapegin,Danila Alexandrovich Kuznetsov,Joseph C. Bear New J. Chem. 2023 47 5270
• 3. Fragment screening libraries for the identification of protein hot spots and their minimal binding pharmacophores
  Rebecca L. Whitehouse,Wesam S. Alwan,Olga V. Ilyichova,Ashley J. Taylor,Indu R. Chandrashekaran,Biswaranjan Mohanty,Bradley C. Doak,Martin J. Scanlon RSC Med. Chem. 2023 14 135
• 4. A sustainable route to produce the scytonemin precursor using Escherichia coli
  Sailesh Malla,Morten O. A. Sommer Green Chem. 2014 16 3255
• 5. Chemistry and biochemistry of 13C hyperpolarized magnetic resonance using dynamic nuclear polarization
  Kayvan R. Keshari,David M. Wilson Chem. Soc. Rev. 2014 43 1627

• Solvents and Organic Chemicals Organic Compounds Benzenoids Benzene and substituted derivatives Benzoic acids
• Solvents and Organic Chemicals Organic Compounds Benzenoids Benzene and substituted derivatives Benzoic acids and derivatives Benzoic acids

Isomerase, Proteindisulfide (CAS No. 37318-49-3): A Comprehensive Overview

The compound CAS No. 37318-49-3, specifically identified as Isomerase, Proteindisulfide, represents a fascinating and increasingly significant molecule in the realm of biochemical research and pharmaceutical development. This enzyme, belonging to the class of isomerases, plays a crucial role in the post-translational modification of proteins, particularly in the formation and rearrangement of disulfide bonds. These bonds are essential for the proper folding and stability of many extracellular proteins, making Isomerase, Proteindisulfide a critical player in various biological processes.

In recent years, the study of Isomerase, Proteindisulfide has gained considerable attention due to its implications in both normal physiology and disease states. Disulfide isomerases are involved in maintaining the correct conformation of proteins, which is vital for their function. Dysfunction in this process can lead to misfolded proteins, a hallmark of several pathological conditions including neurodegenerative diseases and certain types of cancer. The ability of Isomerase, Proteindisulfide to catalyze the rearrangement of disulfide bonds within proteins has opened new avenues for therapeutic intervention.

One of the most compelling aspects of Isomerase, Proteindisulfide is its potential application in drug development. Researchers have been exploring how this enzyme can be harnessed to correct protein misfolding disorders. For instance, studies have shown that modulating the activity of Isomerase, Proteindisulfide can lead to improved protein folding and reduced aggregation, which could be beneficial in treating conditions like Alzheimer's disease and cystic fibrosis. The enzyme's ability to selectively catalyze the formation or breaking of disulfide bonds makes it an attractive target for developing small-molecule drugs that can enhance or inhibit its activity.

The mechanism by which Isomerase, Proteindisulfide operates is also a subject of intense research. This enzyme typically functions within the endoplasmic reticulum (ER) lumen, where it facilitates the correct formation of disulfide bonds during protein synthesis. The ER environment is highly oxidizing, which favors the formation of disulfide bonds between cysteine residues in nascent polypeptides. However, if these bonds are formed incorrectly or if there is an imbalance in oxidizing and reducing conditions within the ER, protein misfolding can occur. Here, Isomerase, Proteindisulfide steps in to correct these misarrangements by catalyzing the rearrangement of disulfide bonds into their correct configurations.

The structural biology of Isomerase, Proteindisulfide has been extensively studied using advanced techniques such as X-ray crystallography and cryo-electron microscopy. These studies have revealed detailed insights into its active site architecture and how it interacts with substrate proteins. Understanding these structural details has been crucial for designing inhibitors or activators that can modulate its activity. For example, recent research has identified specific residues within the active site that are critical for catalytic activity and have led to the development of novel compounds that can enhance or inhibit this enzyme's function.

In addition to its role in protein folding, Isomerase, Proteindisulfide has also been implicated in various cellular signaling pathways. Disulfide bond formation and rearrangement are not only limited to protein maturation but also play a role in regulating cellular processes such as apoptosis and inflammation. Dysregulation of these processes has been linked to several diseases, including cancer and autoimmune disorders. Therefore, targeting Isomerase, Proteindisulfide with therapeutic agents could provide a novel approach to treating these conditions by restoring normal cellular function.

The pharmaceutical industry has taken note of these findings and is actively exploring the potential therapeutic applications of compounds targeting Isomerase, Proteindisulfide. Several clinical trials are underway evaluating the efficacy of small-molecule inhibitors designed to modulate this enzyme's activity. Preliminary results from these trials are promising and suggest that such compounds could be effective in treating protein misfolding disorders without significant side effects. This aligns with the broader goal of developing precision medicine approaches that address specific molecular targets underlying disease pathogenesis.

The future direction of research on CAS No. 37318-49-3, or more accurately termed asCAS No. 37318-49-3 Isomerase Protein Disulfide Isomerase, looks promising with advancements expected not only in understanding its biochemical functions but also in developing innovative therapeutic strategies based on its unique properties.

• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)